Advertisement

Current Treatment Options in Gastroenterology

, Volume 6, Issue 5, pp 427–441 | Cite as

Treatment of gastrointestinal problems in cystic fibrosis

  • Maria R. Mascarenhas
Article

Opinion statement

The gastrointestinal (GI) manifestations of cystic fibrosis (CF) are varied and include pancreatic insufficiency, meconium ileus, distal intestinal obstruction syndrome (DIOS), liver disease, and other less common manifestations. Treatment of pancreatic insufficiency consists of providing appropriate pancreatic enzyme replacement therapy and may include raising duodenal pH to allow for optimal action of these enzymes. Despite a number of pancreatic enzyme replacement products, malabsorption cannot be normalized. Management of DIOS depends on the severity of the symptoms; adequate hydration is very important. Polyethylene glycol solutions are being increasingly used. The precipitating cause of the episode of DIOS should be looked for so future episodes can be prevented. Liver disease is relatively silent and annual monitoring of liver function and status is recommended. Treatment is mainly supportive and the role of ursodeoxycholic acid in the prevention of cirrhosis needs to be better defined. Nutritional status is an important part of management of all GI and liver manifestations of CF. A team approach and the assistance of a registered dietitian are extremely valuable in managing the GI and liver manifestations of CF.

Keywords

Cystic Fibrosis Transjugular Intrahepatic Portosystemic Shunt Rectal Prolapse Pancreatic Enzyme Main Drug Interaction 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Stern RC, Eisenberg JD, Wagener JS, et al.: A comparison of the efficacy and tolerance of pancrelipase and placebo in the treatment of steatorrhea in cystic fibrosis patients with clinical exocrine pancreatic insufficiency. Am J Gastroenterol 2000, 95:1932–1938.PubMedCrossRefGoogle Scholar
  2. 2.
    Millar-Jones L, Goodchild MC: Cystic fibrosis, pancreatic sufficiency and distal intestinal obstruction syndrome: a report of four cases. Acta Paediatr 1995, 84:577–578.PubMedGoogle Scholar
  3. 3.
    Zielenski J, Corey M, Rozmahel R, et al.: Detection of a cystic fibrosis modifier locus for meconium ileus on human chromosome 19q13. Nat Genet 1999, 2:128–129.Google Scholar
  4. 4.
    Minkes RK, Langer JC, Skinner MA, et al.: Intestinal obstruction after lung transplantation in children with cystic fibrosis. J Pediatr Surg 1999, 34:1489–1493.PubMedCrossRefGoogle Scholar
  5. 5.
    Coughlin JP, Gauderer MW, Stern RC, et al.: The spectrum of appendiceal disease in cystic fibrosis. J Pediatr Surg 1990, 25:835–839.PubMedCrossRefGoogle Scholar
  6. 6.
    Del Pin CA, Czyrko C, Ziegler MM, et al.: Management and survival of meconium ileus—a 30-year review. Ann Surg 1992, 215:179–185.PubMedCrossRefGoogle Scholar
  7. 7.
    Baker SS, Liptak GS, Colletti RB, et al.: Constipation in infants and children: evaluation and treatment. J Pediatr Gastroenterol Nutr 1999, 29:612–626.PubMedCrossRefGoogle Scholar
  8. 8.
    Pashankar DS, Bishop WP: Efficacy and optimal dose of daily polyethylene glycol 3350 for treatment of constipation and encopresis in children. J Pediatr 2001, 139:428–432.PubMedCrossRefGoogle Scholar
  9. 9.
    Rubinstein S, Moss R, Lewiston N: Constipation and meconium ileus equivalent in patients with cystic fibrosis. Pediatrics 1986, 78:473–479.PubMedGoogle Scholar
  10. 10.
    Siafakas C, Vottler TP, Andersen JM: Rectal prolapse in pediatrics. Clin Pediatr 1999, 38:63–72.Google Scholar
  11. 11.
    Rudolph CD: Guidelines for evaluation and treatment of gastroesophageal reflux in infants and children. Recommendations of the North American Society for Pediatric Gastroenterology and Nutriiton. J Pediatr Gastroenterol Nutr 2001, 32(suppl 2):S1-S31.PubMedCrossRefGoogle Scholar
  12. 12.
    Hassall E, Israel DM, Davidson AG, et al.: Barrett’s esophagus in children with cystic fibrosis: not a coincidental association. Am J Gastroenterol 1993, 8:1934–1938.Google Scholar
  13. 13.
    Lewindon PJ, Robb TA, Moore DJ, et al.: Bowel dysfunction in cystic fibrosis: importance of breath testing. J Paediatr Child Health 1998, 34:79–82.PubMedCrossRefGoogle Scholar
  14. 14.
    Sharar N, Schwarz M, Malone G, et al.: Mutations of the cystic fibrosis gene in patients with chronic pancreatitis. N Engl J Med 1998, 339:645–652.CrossRefGoogle Scholar
  15. 15.
    Noone PG, Zhou Z, Silverman LM, et al.: Cystic fibrosis gene mutations and pancreatic risk: relation to epithelial ion transport and trypsin inhibitor gene mutations. Gastroenterology 2001, 121:1310–1319.PubMedCrossRefGoogle Scholar
  16. 16.
    Borowitz DS, Grand RJ, Durie PR, et al.: Use of pancreatic enzyme supplements with cystic fibrosis in the context of fibrosing colonopathy. J Pediatr 2001, 127:681–684. This is the first and most comprehensive report from the CF Foundation with guidelines for pancreatic enzyme-replacement therapy and management.Google Scholar
  17. 17.
    FitzSimmons SC, Burkhart GA, Borowitz D, et al.: Highdose pancreatic enzyme supplements and fibrosing colonopathy in children with cystic fibrosis. N Engl J Med 1997, 336:1283–1289.PubMedCrossRefGoogle Scholar
  18. 18.
    Lloyd-Still JD, Beno DW, Kimura RM: Cystic fibrosing colonopathy. Curr Gastroenterol Rep 1999, 1:231–237.PubMedCrossRefGoogle Scholar
  19. 19.
    Chaun H: Colonic disorders in adult cystic fibrosis. Can J Gastroenterol 2001, 15:586–590.PubMedGoogle Scholar
  20. 20.
    Neglia J, FitzSimmons SC, Maisonneuve P, et al.: The risk of cancer among patients with cystic fibrosis. N Engl J Med 1995, 332:494–499.PubMedCrossRefGoogle Scholar
  21. 21.
    Baker RD, Borowitz D, Stallings VA: Consensus report on nutrition for pediatric patients with cystic fibrosis. J Pediatr Gastroenterol Nutr 2002, 35:246–259. This is a comprehensive summary of the nutritional aspects of the management in CF and provides the reader with some excellent information.PubMedCrossRefGoogle Scholar
  22. 22.
    Kraisinger M, Hochhaus G, Stecenko A, et al.: Clinical pharmacology of pancreatic enzymes in patients with cystic fibrosis and in vitro performance of microencapsulated formulations. J Clin Pharmacol 1994, 34:158–166.PubMedGoogle Scholar
  23. 23.
    Meyer JH, Lake R: Mismatch of duodenal deliveries of dietary fat and pancreatin from enterically coated microspheres. Pancreas 1997, 15:226–235.PubMedCrossRefGoogle Scholar
  24. 24.
    Hendeles L, Dorf A, Stecenko A, et al.: Treatment failure after substitution of generic pancrelipase capsules. JAMA 1990, 263:2459–2461.PubMedCrossRefGoogle Scholar
  25. 25.
    Durie PR, Bell L, Linton W, et al.: Effect of cimetidine and sodium bicarbonate on pancreatic replacement therapy in cystic fibrosis. Gut 1980, 21:778–786.PubMedGoogle Scholar
  26. 26.
    Tran TM, Van den Neucker A, Hendriks JJ, et al.: Effects of a proton-pump inhibitor in cystic fibrosis. Acta Paediatr 1998, 87:553–558.PubMedCrossRefGoogle Scholar
  27. 27.
    DiMagno EP: Gastric acid suppression and treatment of severe exocrine pancreatic insufficiency. Best Practice Res Clin Gastroenterol 2001, 15:477–486.CrossRefGoogle Scholar
  28. 28.
    Kreimler S, Wilk B, Schurer W, et al.: Preventing dehydration in children with cystic fibrosis who exercise in the heat. Med Sci Spots Exerc 1999, 31:774–779.CrossRefGoogle Scholar
  29. 29.
    Koletzko S, Stringer DA, Cleghorn GJ, et al.: Lavage treatment of distal obstruction intestinal syndrome in children with cystic fibrosis. Pediatrics 1989, 83:727–733.PubMedGoogle Scholar
  30. 30.
    Ellis GJ, Dewar AL, Rolles CJ, et al.: Dietary fiber and the occurrence of gut symptoms in cystic fibrosis. Arch Dis Child 1997, 76:35–37.PubMedCrossRefGoogle Scholar
  31. 31.
    Sokol RJ, Durie PR, and the CF Foundation Hepatobiliary disease consensus group: Recommendations for the management of liver and biliary tract disease in cystic fibrosis. J Pediatr Gastenterol Nutr 1999, 28:S1-S13.CrossRefGoogle Scholar
  32. 32.
    Colombo C, Battezzati PM, Podda M, et al.: Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-blind multicenter trial. The Italian group for the study of ursodeoxycholic acid in cystic fibrosis. Hepatology 1996, 23:1484–1490.PubMedCrossRefGoogle Scholar
  33. 33.
    Lindblad A, Glaumann H, Strandvick B: A two-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis-associated liver disease. Hepatology 1998, 27:166–174.PubMedCrossRefGoogle Scholar
  34. 34.
    Narkewicz MR, Smith D, Gregory C, et al.: Effect of ursodeoxyholic acid therapy on hepatic function in children with intrahepatic cholestasis. J Pediatr Gastro Nutr 1998, 26:49–55.CrossRefGoogle Scholar
  35. 35.
    Paumgartner G: Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology 2002, 36:525–531.PubMedCrossRefGoogle Scholar
  36. 36.
    Colombo C, Crosgnani A, Assaisso M, et al.: Ursodeoxycholic therapy in cystic fibrosis-associated liver disease: a dose-response study. Hepatology 1992, 16:924–930.PubMedCrossRefGoogle Scholar
  37. 37.
    Cheng K, Ashby D, Smythe R: Ursodeoxycholic acid for cystic fibrosis-related liver disease. Cochrane Database of Systematic Reviews 2000, 2:CD000222.Google Scholar
  38. 38.
    Colombo C, Bertolini E, Assaisso ML, et al.: Failure of ursodeoxycholic acid to dissolve radiolucent gallstones in patients with cystic fibrosis. Acta Paeditr 1993, 82:562–565.Google Scholar
  39. 39.
    Strandvick B, Hultcrantz R: Liver function and morphology during long-term fatty acid supplementation in cystic fibrosis. Liver 1994, 14:32–36.Google Scholar
  40. 40.
    Debray D, Lykavieris P, Gauthier F, et al.: Outcome of cystic fibrosis-associated liver cirrhosis: management of portal hypertension. J Hepatol 1999, 31:77–83.PubMedCrossRefGoogle Scholar
  41. 41.
    Genyk YS, Quiros JA, Jabbour N, et al.: Liver transplantation in cystic fibrosis. Curr Opin Pulmon Med 2001, 7:441–447.CrossRefGoogle Scholar
  42. 42.
    Lindblad A, Glaumann H, Strandvik B: Natural history of liver disease in cystic fibrosis. Hepatology 1999, 30:1151–1158.PubMedCrossRefGoogle Scholar
  43. 43.
    Diwakar V, Pearson L, Beath S: Liver disease in children with cystic fibrosis. Paediatric Resp Rev 2001, 2:340–349.CrossRefGoogle Scholar

Copyright information

© Current Science Inc 2003

Authors and Affiliations

  • Maria R. Mascarenhas
    • 1
    • 2
  1. 1.Division of GI and NutritionThe Children’s Hospital of PhiladelphiaPhiladelphiaUSA
  2. 2.Division of GI and NutritionUniversity of Pennsylvania School of MedicinePhiladelphiaUSA

Personalised recommendations